JP2011523647A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011523647A5 JP2011523647A5 JP2011510798A JP2011510798A JP2011523647A5 JP 2011523647 A5 JP2011523647 A5 JP 2011523647A5 JP 2011510798 A JP2011510798 A JP 2011510798A JP 2011510798 A JP2011510798 A JP 2011510798A JP 2011523647 A5 JP2011523647 A5 JP 2011523647A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- alkyl
- ring members
- compound
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 45
- 125000000623 heterocyclic group Chemical group 0.000 claims description 30
- 239000008194 pharmaceutical composition Substances 0.000 claims description 29
- 125000000217 alkyl group Chemical group 0.000 claims description 28
- 125000004404 heteroalkyl group Chemical group 0.000 claims description 28
- 125000001424 substituent group Chemical group 0.000 claims description 27
- 125000003342 alkenyl group Chemical group 0.000 claims description 25
- 125000000304 alkynyl group Chemical group 0.000 claims description 25
- 125000005843 halogen group Chemical group 0.000 claims description 20
- 150000003839 salts Chemical class 0.000 claims description 15
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 14
- 125000001072 heteroaryl group Chemical group 0.000 claims description 13
- 125000003118 aryl group Chemical group 0.000 claims description 10
- 230000000694 effects Effects 0.000 claims description 10
- 125000004122 cyclic group Chemical group 0.000 claims description 9
- -1 difluoromethoxy, trifluoromethoxy, methylsulfonyl Chemical group 0.000 claims description 9
- 208000002193 Pain Diseases 0.000 claims description 8
- 229910052799 carbon Inorganic materials 0.000 claims description 8
- 125000004432 carbon atom Chemical group C* 0.000 claims description 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 7
- 206010015037 epilepsy Diseases 0.000 claims description 6
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 6
- 108090000312 Calcium Channels Proteins 0.000 claims description 5
- 102000003922 Calcium Channels Human genes 0.000 claims description 5
- 208000008589 Obesity Diseases 0.000 claims description 5
- 102000003691 T-Type Calcium Channels Human genes 0.000 claims description 5
- 108090000030 T-Type Calcium Channels Proteins 0.000 claims description 5
- 125000004450 alkenylene group Chemical group 0.000 claims description 5
- 125000002947 alkylene group Chemical group 0.000 claims description 5
- 125000004474 heteroalkylene group Chemical group 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- 235000020824 obesity Nutrition 0.000 claims description 5
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 4
- 208000000094 Chronic Pain Diseases 0.000 claims description 4
- 208000005298 acute pain Diseases 0.000 claims description 4
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims description 4
- 230000001684 chronic effect Effects 0.000 claims description 4
- 125000002883 imidazolyl group Chemical group 0.000 claims description 4
- 125000001041 indolyl group Chemical group 0.000 claims description 4
- 125000000842 isoxazolyl group Chemical group 0.000 claims description 4
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 4
- 125000004076 pyridyl group Chemical group 0.000 claims description 4
- 125000000335 thiazolyl group Chemical group 0.000 claims description 4
- 125000001544 thienyl group Chemical group 0.000 claims description 4
- 125000001246 bromo group Chemical group Br* 0.000 claims description 3
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 3
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 3
- 125000001153 fluoro group Chemical group F* 0.000 claims description 3
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 3
- 206010058019 Cancer Pain Diseases 0.000 claims description 2
- 206010020853 Hypertonic bladder Diseases 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 claims description 2
- 208000009722 Overactive Urinary Bladder Diseases 0.000 claims description 2
- 208000018737 Parkinson disease Diseases 0.000 claims description 2
- 208000028017 Psychotic disease Diseases 0.000 claims description 2
- 230000033228 biological regulation Effects 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 claims description 2
- 206010012601 diabetes mellitus Diseases 0.000 claims description 2
- 230000035558 fertility Effects 0.000 claims description 2
- 208000017169 kidney disease Diseases 0.000 claims description 2
- 230000004112 neuroprotection Effects 0.000 claims description 2
- 208000020629 overactive bladder Diseases 0.000 claims description 2
- 208000019116 sleep disease Diseases 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 3
- 125000003107 substituted aryl group Chemical group 0.000 description 3
- 0 *c1cc(C(NCC2CCN(*)CC2)=O)cc(*)c1 Chemical compound *c1cc(C(NCC2CCN(*)CC2)=O)cc(*)c1 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 208000020685 sleep-wake disease Diseases 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US5818508P | 2008-06-02 | 2008-06-02 | |
| US5817908P | 2008-06-02 | 2008-06-02 | |
| US61/058,185 | 2008-06-02 | ||
| US61/058,179 | 2008-06-02 | ||
| US12/420,793 US8377968B2 (en) | 2008-06-02 | 2009-04-08 | N-piperidinyl acetamide derivatives as calcium channel blockers |
| US12/420,793 | 2009-04-08 | ||
| PCT/CA2009/000768 WO2009146540A1 (en) | 2008-06-02 | 2009-06-02 | N-piperidinyl acetamide derivatives as calcium channel blockers |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011523647A JP2011523647A (ja) | 2011-08-18 |
| JP2011523647A5 true JP2011523647A5 (cg-RX-API-DMAC7.html) | 2012-07-19 |
| JP5560264B2 JP5560264B2 (ja) | 2014-07-23 |
Family
ID=41380590
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011510798A Active JP5560264B2 (ja) | 2008-06-02 | 2009-06-02 | カルシウムチャネルブロッカーとしてのｎ−ピペリジニルアセトアミド誘導体 |
Country Status (16)
| Country | Link |
|---|---|
| US (4) | US8377968B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP2300007B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP5560264B2 (cg-RX-API-DMAC7.html) |
| KR (3) | KR101722898B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN102695506B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2009253797B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BRPI0915295B1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2725355C (cg-RX-API-DMAC7.html) |
| CY (1) | CY1123466T1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2677911T3 (cg-RX-API-DMAC7.html) |
| HR (1) | HRP20201243T1 (cg-RX-API-DMAC7.html) |
| IL (2) | IL209581A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2010013208A (cg-RX-API-DMAC7.html) |
| PL (1) | PL3189839T3 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2009146540A1 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA201008838B (cg-RX-API-DMAC7.html) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8362021B2 (en) * | 2006-05-11 | 2013-01-29 | Zalicus Pharmaceuticals Ltd. | Method for increasing the bioavailability of benzhydryl piperazine containing compounds |
| KR20120081119A (ko) * | 2009-09-04 | 2012-07-18 | 잘리커스 파마슈티컬즈 리미티드 | 통증 및 간질 치료를 위한 치환된 헤테로고리 유도체 |
| WO2011032291A1 (en) * | 2009-09-18 | 2011-03-24 | Zalicus Pharmaceuticals Ltd . | Selective calcium channel modulators |
| US8409560B2 (en) | 2011-03-08 | 2013-04-02 | Zalicus Pharmaceuticals Ltd. | Solid dispersion formulations and methods of use thereof |
| KR20140011366A (ko) | 2011-03-08 | 2014-01-28 | 잘리커스 파마슈티컬즈 리미티드 | 고체 분산체 제형 및 그의 이용방법 |
| EP2567959B1 (en) | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| GEP20166489B (en) * | 2012-02-21 | 2016-06-10 | Acraf | 1h-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta inhibitors |
| RU2645158C2 (ru) | 2012-03-30 | 2018-02-16 | Ниссан Кемикал Индастриз, Лтд. | Соединение триазинона и ингибитор кальциевых каналов т-типа |
| WO2014134306A1 (en) | 2013-03-01 | 2014-09-04 | Zalicus Pharmaceuticals, Ltd. | Heterocyclic inhibitors of the sodium channel |
| US20160237071A1 (en) | 2013-10-02 | 2016-08-18 | Nissan Chemical Industries, Ltd. | T-type calcium channel inhibitor |
| EP3085695A1 (en) | 2013-12-17 | 2016-10-26 | Nissan Chemical Industries, Ltd. | Substituted triazinone compound and t-type calcium channel inhibitor |
| CA3002831C (en) | 2015-10-22 | 2024-04-16 | Cavion, Inc. | Methods for treating angelman syndrome and related disorders |
| CN108289886B (zh) * | 2015-11-12 | 2022-01-28 | 安华赛公司 | 离子通道抑制化合物、药物制剂和用途 |
| US20210128537A1 (en) * | 2016-12-21 | 2021-05-06 | Praxis Precision Medicines, Inc. | T-type calcium channel modulators and methods of use thereof |
| KR102642063B1 (ko) | 2017-02-15 | 2024-03-04 | 카비온, 인코포레이티드 | 칼슘 채널 억제제 |
| EP3615521A4 (en) | 2017-04-26 | 2021-02-17 | Cavion, Inc. | METHODS FOR IMPROVING MEMORY AND COGNITION AND TREATING MEMORY AND COGNITIVE DISORDERS |
| RU2767661C2 (ru) * | 2017-04-26 | 2022-03-18 | Кавион, Инк. | Способы лечения синдрома драве |
| AU2019355021B2 (en) | 2018-10-03 | 2024-09-12 | Cavion, Inc. | Treating essential tremor using (R)-2-(4-Isopropylphenyl)-N-(1-(5-(2,2,2-Trifluoroethoxy)pyridin-2-yl)ethyl)acetamide |
| MX2022000492A (es) | 2019-07-11 | 2022-07-04 | Praxis Prec Medicines Inc | Formulaciones de moduladores de canal de calcio tipo t y metodos de uso de estos. |
| CN115776894A (zh) * | 2020-04-29 | 2023-03-10 | 普拉西斯精密医药公司 | T型钙通道调节剂的使用方法 |
| CN116669724A (zh) * | 2020-11-09 | 2023-08-29 | 普拉西斯精密医药公司 | T型钙通道调节剂和其使用方法 |
| TW202233578A (zh) * | 2020-11-09 | 2022-09-01 | 美商普雷西斯精密藥品公司 | Ｔ型鈣離子通道調節劑及其使用方法 |
| CN117715641A (zh) * | 2021-04-26 | 2024-03-15 | 普拉西斯精密医药公司 | 用神经活性类固醇进行治疗的方法 |
| CN114518425B (zh) * | 2022-02-11 | 2023-03-10 | 中国科学技术大学 | 同时检测单个免疫细胞胞浆和细胞膜的代谢物的分析方法 |
| JP2025511181A (ja) * | 2022-04-01 | 2025-04-15 | プラクシス プレシジョン メディシンズ， インコーポレイテッド | アザスピロノナンコアを含むｔ型カルシウムチャネル調節因子及びその使用方法 |
| WO2023192665A2 (en) * | 2022-04-01 | 2023-10-05 | Praxis Precision Medicines, Inc. | T-type calcium channel modulators and methods of use thereof |
| CN119584962A (zh) * | 2022-05-09 | 2025-03-07 | 普拉西斯精密医药公司 | T型钙通道调节剂的使用方法 |
| CN121013719A (zh) * | 2023-03-02 | 2025-11-25 | 普拉西斯精密医药公司 | 治疗特发性震颤的方法 |
| IL322960A (en) * | 2023-03-02 | 2025-10-01 | Praxis Prec Medicines Inc | High-strength single-unit dosage formulations and methods of using them |
| WO2025188619A1 (en) * | 2024-03-04 | 2025-09-12 | Praxis Precision Medicines, Inc. | Methods of treating parkinson's disease with t-type calcium channel modulators |
| WO2025255502A1 (en) | 2024-06-07 | 2025-12-11 | Cavion, Inc. | PYRIDYL AMIDE Cav3 CHANNEL MODULATORS |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5852014A (en) | 1992-03-12 | 1998-12-22 | Smithkline Beecham P.L.C. | Condensed indole derivatives as 5HT4 -receptor antagonists |
| US5624677A (en) | 1995-06-13 | 1997-04-29 | Pentech Pharmaceuticals, Inc. | Controlled release of drugs delivered by sublingual or buccal administration |
| JPH11513382A (ja) * | 1995-10-20 | 1999-11-16 | ドクトル カルル トーマエ ゲゼルシャフト ミット ベシュレンクテル ハフツング | ５員複素環化合物、これらの化合物を含む医薬品、それらの使用及びそれらの調製方法 |
| IT1291569B1 (it) * | 1997-04-15 | 1999-01-11 | Angelini Ricerche Spa | Indazolammidi come agenti serotoninergici |
| IL125658A0 (en) | 1997-08-18 | 1999-04-11 | Hoffmann La Roche | Ccr-3 receptor antagonists |
| FR2769914B1 (fr) | 1997-10-21 | 2000-02-04 | Synthelabo | Derives d'indazole tricycliques leur preparation et leur application en therapeutique |
| US20030125269A1 (en) | 1998-08-26 | 2003-07-03 | Ming Li | T-type calcium channel |
| TW570920B (en) | 1998-12-22 | 2004-01-11 | Janssen Pharmaceutica Nv | 4-(aminomethyl)-piperidine benzamides for treating gastrointestinal disorders |
| GR20000100283A (el) * | 2000-08-17 | 2002-05-24 | Κωνσταντινος Αλεξοπουλος | Μη-πεπτιδικοι μιμητες της δραστικης αλληλουχιας s42fllr46 του υποδοχεα της θρομβινης για την θεραπεια της θρομβωσης και του καρκινου |
| EP1217000A1 (en) | 2000-12-23 | 2002-06-26 | Aventis Pharma Deutschland GmbH | Inhibitors of factor Xa and factor VIIa |
| CA2443108A1 (en) | 2001-04-03 | 2002-10-17 | Merck & Co. Inc. | N-substituted nonaryl-heterocyclo amidyl nmda/nr2b antagonists |
| WO2003007953A1 (en) | 2001-07-18 | 2003-01-30 | Washington University | Methods and compositions for modulating t-type calcium channels |
| KR100534556B1 (ko) | 2001-10-26 | 2005-12-08 | 주식회사 오리엔트바이오 | 알파１ｇ 단백질의 기능을 억제하여 간질을 일으키지 않게하는 방법 |
| KR20030037081A (ko) | 2001-11-02 | 2003-05-12 | 한국과학기술연구원 | Ｔ 타입 칼슘채널을 조절하여 복통을 억제하는 방법 |
| GB0126781D0 (en) | 2001-11-07 | 2002-01-02 | Medical Res Council | Modulation |
| DE10227511A1 (de) | 2002-06-19 | 2004-01-08 | Max-Delbrück-Centrum für Molekulare Medizin | Mittel zur medikamentösen Behandlung von akuten und chronischen Schmerzen |
| US20060003985A1 (en) | 2002-10-17 | 2006-01-05 | Renger John J | Enhancement of sleep with t-type calcium channel antagonists |
| AU2003284402A1 (en) | 2002-11-15 | 2004-06-15 | Yamanouchi Pharmaceutical Co., Ltd. | Antagonist to melanin-concentrating hormone receptor |
| WO2004065576A2 (en) | 2003-01-15 | 2004-08-05 | Millennium Pharmaceuticals, Inc. | Methods and compositions for the treatment of urological disorder using differential expressed polypeptides |
| CA2527159A1 (en) | 2003-05-30 | 2004-12-09 | Neuromed Technologies, Inc. | 3-aminomethyl-pyrrolidines as n-type calcium channel blockers |
| US7507760B2 (en) | 2004-01-22 | 2009-03-24 | Neuromed Pharmaceuticals Ltd. | N-type calcium channel blockers |
| EP2319536A1 (en) | 2004-02-11 | 2011-05-11 | University Of Virginia Patent Foundation | Inhibiting CAV3 isoforms and the delta25B splice varients for the diagnosis and treatment of cancer |
| WO2005092882A1 (en) | 2004-03-01 | 2005-10-06 | Pfizer Japan, Inc. | 4-amino-5-halogeno-benzamide derivatives as 5-ht4 receptor agonists for the treatment of gastrointestinal, cns, neurological and cardiovascular disorders |
| US20060003020A1 (en) | 2004-03-11 | 2006-01-05 | The Regents Of The University Of Michigan | Anti-metastatic ability of mibefradil and gadolinium |
| US7888374B2 (en) * | 2005-01-28 | 2011-02-15 | Abbott Laboratories | Inhibitors of c-jun N-terminal kinases |
| CA2611153A1 (en) | 2005-06-23 | 2007-01-04 | Merck & Co., Inc. | 3-fluoro-piperidine t-type calcium channel antagonists |
| AU2006263564A1 (en) | 2005-06-29 | 2007-01-04 | Merck Sharp & Dohme Corp. | 4-fluoro-piperidine T-type calcium channel antagonists |
| EP1943215A2 (en) | 2005-10-31 | 2008-07-16 | Brystol-Myers Squibb Company | Pyrrolidinyl beta-amino amide-based inhibitors of dipeptidyl peptidase iv and methods |
| CA2669736C (en) * | 2005-11-03 | 2017-02-21 | Chembridge Research Laboratories, Inc. | Heterocyclic compounds as tyrosine kinase modulators |
| EP1966130B1 (en) | 2005-12-23 | 2013-12-11 | Zealand Pharma A/S | Modified lysine-mimetic compounds |
| US20090156465A1 (en) | 2005-12-30 | 2009-06-18 | Sattigeri Jitendra A | Derivatives of beta-amino acid as dipeptidyl peptidase-iv inhibitors |
| EP2061780A4 (en) | 2006-09-14 | 2010-12-22 | Zalicus Pharmaceuticals Ltd | DIARYLE PIPERIDINE COMPOUNDS AS CALCIUM CHANNEL BLOCKERS |
| US20090298834A1 (en) | 2008-06-02 | 2009-12-03 | Hassan Pajouhesh | 4-(aminomethyl)cyclohexanamine derivatives as calcium channel blockers |
| WO2011032291A1 (en) | 2009-09-18 | 2011-03-24 | Zalicus Pharmaceuticals Ltd . | Selective calcium channel modulators |
-
2009
- 2009-04-08 US US12/420,793 patent/US8377968B2/en active Active
- 2009-06-02 CN CN200980129679.1A patent/CN102695506B/zh active Active
- 2009-06-02 KR KR1020167032345A patent/KR101722898B1/ko active Active
- 2009-06-02 EP EP09757002.2A patent/EP2300007B1/en active Active
- 2009-06-02 KR KR1020107028775A patent/KR101909749B1/ko active Active
- 2009-06-02 EP EP17155716.8A patent/EP3189839B1/en active Active
- 2009-06-02 AU AU2009253797A patent/AU2009253797B2/en active Active
- 2009-06-02 ES ES09757002.2T patent/ES2677911T3/es active Active
- 2009-06-02 BR BRPI0915295-4A patent/BRPI0915295B1/pt active IP Right Grant
- 2009-06-02 CA CA2725355A patent/CA2725355C/en active Active
- 2009-06-02 WO PCT/CA2009/000768 patent/WO2009146540A1/en not_active Ceased
- 2009-06-02 JP JP2011510798A patent/JP5560264B2/ja active Active
- 2009-06-02 MX MX2010013208A patent/MX2010013208A/es unknown
- 2009-06-02 PL PL17155716T patent/PL3189839T3/pl unknown
- 2009-06-02 KR KR1020187029396A patent/KR20180115346A/ko not_active Ceased
-
2010
- 2010-11-25 IL IL209581A patent/IL209581A/en active IP Right Grant
- 2010-12-08 ZA ZA2010/08838A patent/ZA201008838B/en unknown
-
2012
- 2012-08-31 US US13/601,357 patent/US8569344B2/en active Active
-
2013
- 2013-08-29 US US14/013,934 patent/US9096522B2/en active Active
-
2015
- 2015-06-29 US US14/753,936 patent/US20160175315A1/en not_active Abandoned
-
2017
- 2017-03-20 IL IL251281A patent/IL251281B/en active IP Right Grant
-
2020
- 2020-08-07 HR HRP20201243TT patent/HRP20201243T1/hr unknown
- 2020-08-14 CY CY20201100761T patent/CY1123466T1/el unknown